 we present our financial results for the first quarter ended on march 31, 2022. 
 we report a net loss of $2.7 million or $0.26 per diluted share for the three - months ended March 31, 2022 compared to a net loss of $1.5 million or $0.21 per diluted share for the three - months ended on December 31, 2021.  we also report a net loss of $11.1 million for the quarter ended on march 31, 2022 compared to a net loss of $13 million for the three - months ended on December 31, 2021.    
 the first quarter of 2022 was particularly exciting for our company because more patients were enrolled in the first clinical trial of ibezapolstat, our leading antibiotic candidate for the treatment of patients with acute c. difficile infection.    
 we are particularly excited about the impact of ibezapolstat on the microbiome and the impact of ibezapolstat on treating acute c. difficile infection. 
 based on the strength of our previously reported phase 2a results, which demonstrated 100% clinical cure in patients after a 10-day treatment for acute c. difficile infection with no recurrence of